Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report.
Sergio Bracarda
Consultant or Advisory Role - Astellas Pharma; Bayer; Janssen Pharmaceutical ; Sanofi
Honoraria - Astellas Pharma; Bayer; Janssen Pharmaceutical ; Sanofi
Giuseppe Procopio
Consultant or Advisory Role - Bayer; Janssen Pharmaceutical
Honoraria - Bayer; Janssen Pharmaceutical
Daniele Alesini
No relevant relationships to disclose
Francesco Grillone
No relevant relationships to disclose
Francesco Massari
No relevant relationships to disclose
Alberto Zaniboni
No relevant relationships to disclose
Rodolfo Mattioli
No relevant relationships to disclose
Sebastiano Buti
No relevant relationships to disclose
Enrico Garanzini
No relevant relationships to disclose
Michele Sisani
No relevant relationships to disclose
Alketa Hamzaj
No relevant relationships to disclose
Amelia Altavilla
No relevant relationships to disclose
Verena De Angelis
No relevant relationships to disclose